Evaluating the Safety and Efficacy of Edaravone-Dexborneol in Acute Ischemic Stroke Patients (P8-4.012)
作者
Noor Naeem,Syeda Azra Batool,Hafiz U Shibli,Aqsa Fareed,Irfan Ullah,Musfirah Imtiaz,Amber Naeem,Haider Imran,Hira Khan,Muhammad Saeed Qazi,Ayesha Ashar,Anoosh Farooqui
出处
期刊:Neurology [Lippincott Williams & Wilkins] 日期:2026-06-09卷期号:106 (11_Supplement_1)
标识
DOI:10.1212/wnl.0000000000213036
摘要
Objective To evaluate the safety and efficacy of Edaravone-dexborneol in patients with AIS by synthesizing evidence from randomized controlled trials and observational studies. Background Each year, approximately 15 million people suffer an acute ischemic stroke worldwide , of which 5 million suffer death and another 5 million are left with long-term disability. Existing treatments exhibit limited efficacy, warranting the investigation of novel therapeutic strategies. Edaravone and Dexborneol have surfaced as potential treatments for AIS, showing promise in facilitating neurological recovery and mobility. Design/Methods We conducted a systematic review of PubMed, ClinicalTrials.gov , and Google Scholar through October 2024 to identify RCTs and observational studies assessing Edaravone-dexborneol in AIS. Studies were screened for functional outcomes using the modified Rankin Scale (mRS), safety events, and biomarker changes. Results The findings indicate that the combination of Edaravone-dexborneol decreases the infarct size, oxidative stress, and inflammation in ischemic brain regions. RCTs demonstrated significant improvements in 90-day functional recovery with Edaravone-dexborneol compared with Edaravone alone or standard therapy. One multicenter phase III RCT reported favorable mRS outcomes in 67.2% of patients receiving Edaravone-dexborneol versus 59.0% with Edaravone alone (OR 1.42, 95% CI 1.12–1.81; p=0.004). Another phase II trial found 70.7% of patients achieved mRS <2 versus 47.8% with standard therapy (p=0.031). Across studies, serious adverse events were infrequent, and the safety profile was comparable to existing treatments. Conclusions This is among the first reviews synthesizing clinical trial evidence on Edaravone-dexborneol, by filling in the translational gap and exhibiting the safety and efficacy of this neuroprotective adjunct in improving outcomes in AIS. Current evidence is largely limited to Asian populations with short follow-up periods. Larger multicenter trials across diverse populations are needed to validate long-term efficacy and safety. If validated in diverse populations, this therapy provides neurologists with a neuroprotective adjunct to current AIS treatments and expands treatment options beyond time-limited reperfusion strategies. Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff. Disclosure: Miss Naeem has nothing to disclose. Miss Batool has nothing to disclose. Dr. Shibli has nothing to disclose. Dr. Fareed has nothing to disclose. Mr. Ullah has nothing to disclose. Dr. imtiaz has nothing to disclose. Miss Naeem has nothing to disclose. Dr. Imran has nothing to disclose. Miss Khan has nothing to disclose. Mr. Qazi has nothing to disclose. Miss Ashar has nothing to disclose. Dr. Farooqui has nothing to disclose.